PREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DM

NCT07795918 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2026-08-31

No results posted yet for this study

Summary

The goal of this observational study is to learn whether community pharmacy-based risk assessment and point-of-care HbA1c testing can help detect undiagnosed type 2 diabetes and prediabetes among adults in Irbid Governorate, Jordan, who have no previous diabetes diagnosis.

The main questions it aims to answer are:

What proportion of participants fall into each Finnish Diabetes Risk Score category? What proportion of participants at high or very high risk have HbA1c results within the prediabetes or diabetes range?

Participants will:

Complete the Finnish Diabetes Risk Score questionnaire at a community pharmacy. Receive a finger-prick HbA1c test at the pharmacy if their risk score is 15 or higher.

Visit a general practitioner or primary care facility for diagnostic confirmation if their HbA1c result is abnormal.

Attend follow-up assessments at three and six months if a general practitioner confirms type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2
  • Prediabetic State
  • Prediabetes / Type 2 Diabetes
  • T2DM

Sponsors & Collaborators

  • Universiti Sains Malaysia

    lead OTHER

Principal Investigators

  • Rabia Hussain, RPh, PhD · Universiti Sains Malaysia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2027-03-31
Completion
2027-05-31

Countries

  • Jordan

Study Locations

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07795918 on ClinicalTrials.gov